(PURI) PuriCore
Summary
|
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||
| Headline | Source | |||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Fri 15:22 | RNS |
|||||||||||||||||||||||||||||||||||||||||||||||
|
RNS Number : 7975W PuriCore Plc 03 February 2012 PuriCore plc
Directors Dealings and Share Option Grants
MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 3 February 2012 - PuriCore (LSE: PURI), the life sciences company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, announces today directors dealings and share option grants, in accordance with the Disclosure and Transparency Rules.
Director Dealings
The Company announces that on 1 February 2012 the following Director purchased shares in the Company, as set out below.
Non-Executive Director Share Option Grants
PuriCore also announces it has issued share options to the Company's Non-Executive Directors as set forth below. The share options have an exercise price of 61.43p, which is five per cent over the closing market price of the Company's ordinary shares on 2 February 2012, and a five-year term.
*As announced 1 February 2012.
Enquiries:
About PuriCore PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology offers a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. PuriCore's Solutions are proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK.
To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.
This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||||||||||||
| 02-02-12 | RNS |
|||||||||||||||||||||||||||||||||||||||||||||||
|
RNS Number : 7262W PuriCore Plc 02 February 2012 BLOCK LISTING SIX MONTHLY RETURN * Information provided on this form must be typed or printed electronically and provided to an ris. Date: 2 February 2012
* Note securities above reflect the 1 to 10 share consolidation effective 2 July 2010.
This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||||||||||||
| 01-02-12 | RNS |
|||||||||||||||||||||||||||||||||||||||||||||||
|
RNS Number : 5690W PuriCore Plc 01 February 2012 BBSRC grants an Industrial Partner award to The University of Oxford to Study PuriCore's ActiVita™ Agricultural Fungicide Solution
MALVERN, PENNSYLVANIA AND STAFFORD, UK, 1 February 2012- PuriCore(LSE: PURI), the water-based clean technology company, today announces the award of £500,000 by the Biotechnology and Biological Sciences Research Council (BBSRC) in a research grant to The University of Oxford to study PuriCore's ActiVita Agricultural Solution, a proprietary, environmentally safe fungicidal solution formulated for agricultural applications. The three-year grant will fund research focused on exploring the mode of action of the ActiVita solution on fungi that devastate major food crops, including wheat, rice, and maize. The research will be led by Sarah Gurr, PhD, Professor of Molecular Plant Pathology at The University of Oxford, a specialist in crop disease, plant pathogenic fungi, and fungal biotechnology.
Christopher Wightman, Executive Chairman, said: "There is clearly a large and growing need to advance plant protection whilst ensuring the safety of food crops. The annual fungicide market is valued at approximately $12 billion worldwide, yet substantial crop loss due to pathogen infestation continues to be a major issue. Based on our research to-date, we believe that ActiVita could represent a significant scientific advancement in protecting important food crops from plant disease without causing harm to the plant or to the environment. This grant allows both Professor Gurr to continue her research and PuriCore to advance towards commercialisation of this highly effective and environmentally safe technology to improve global agricultural productivity and protect the food supply."
Sarah Gurr, PhD, Professor of Molecular Plant Pathology, at The University of Oxford, said: "Extant fungal strains, and now even more aggressively threatening emerging strains, pose a serious threat to our annual harvests and so challenge global food security. Several fungi have become resistant to single-target site fungicides. Our research reveals that ActiVita is a potent antifungal and shows potential to protect plants from these devastating pathogens. We believe ActiVita could represent a major breakthrough as a safe and effective fungicide."
The BBSRC is funded by the UK Government's Department for Business, Innovation and Skills, with a 2011-2012 budget of £445 million to support approximately 1600 scientists and 2000 research students in universities and institutes in the UK.
-Ends-
Enquiries:
About the Fungicide Market The global demand for food crops is increasing rapidly, as the population surpasses 7 billion, and correspondingly, the demand for fungicides to protect those crops increases. The fungicide market is expected to reach $12.1 billion in 2012, up from $8.3 billion in 20071. A third of all fungicides are used to treat cereal crops, including wheat, rice, and maize. Each crop is challenged by fungal pathogens: 10-30% of harvestable rice is lost to the rice blast fungus; 10-70% of harvestable wheat is lost due to stem rust infection; and 2-20% of harvestable maize is lost to corn smut.
About PuriCore PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively and naturally kill infectious pathogens without causing harm to human health or the environment. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. The Company's technologies are proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK.
To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.
1 Cropnosis 2007
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||||||||||||
| 01-02-12 | RNS |
|||||||||||||||||||||||||||||||||||||||||||||||
|
RNS Number : 5688W PuriCore Plc 01 February 2012 PuriCore plc
Appointment of New Independent Non-Executive Director
MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 1 February 2012 - PuriCore(LSE: PURI), the life sciences company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, announces that it has named Michael R.D. Ashton, as Independent Non-Executive Director with immediate effect.
Mr. Ashton brings more than 30 years of pharmaceutical, biotechnology, and medical device industry experience including senior positions at Merck Inc. and Pfizer Inc. as well as holding a number of CEO positions at Purepac Inc., Faulding Inc., SkyePharma plc and most recently at LMA, NV.He will serve as Chairman of PuriCore's Remuneration Committee and on the Audit and Nomination Committees. Mr. Ashton is also a Non-Executive Director of Hikma Pharmaceuticals Plc, Proximagen Group Plc, and Transition Therapeutics Inc. and serves as a pharma consultant to Nations Investment Company. Mr. Ashton (aged 65) holds a B. Pharma from Sydney University and an MBA from Rutgers University.
Mr. Ashton will receive options to purchase 35,000 shares of PuriCore ordinary shares. Each share option will have a five-year life and vest one-half per year beginning on the first anniversary of grant. The exercise price will be five per cent over the market price of the Company's ordinary shares on the date of grant (2nd February 2012).
Chris Wightman, Executive Chairman of PuriCore, said: "We welcome the addition of Michael's extensive industry experience and impressive track record to our Board. Michael joins at an important stage of the Company's development and will be a valuable asset as we continue to drive PuriCore's profitability and pursue new markets and opportunities to grow the business."
There are no further details to be disclosed in relation to the Financial Services Authority UK Listing Rules. Form AP01 confirming the appointment of Mr. Ashton has been submitted to the Registrar of Companies.
Enquiries:
About PuriCore PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology offers a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. PuriCore's Solutions are proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK.
To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||||||||||||
| Result Pages: 1 | ||||
| Date/Time | Subject | Author | ||
|---|---|---|---|---|
| 01-02-12 |
1 |
|||
|
|
||||
|
|
||||
|
I wouldn't recognise an Elliot Wave if I got drenched by one
Don't think I've ever based an investment decision yet on technicals of any sort, but my eye was caught by seeming reliability of the GC, borne out by some retrospective checking of other shares I hold... No matter, today has been a good day! |
||||
| 01-02-12 |
1 |
|||
|
|
||||
|
|
||||
|
sd - well I dont know anything about PURI, but the longterm chart shows a lot of pain! 850p top back in 2006, followed by the relentless fall! MOre recently the SP nearly trebling from the Aug 2010 lows!
I hope it recovers some more for you, but despite todays big rise, a bit of consolidation looks likely, as thecharts a tad toppy. Its also debatable how far markets can go, and whether there will be a more sustained run up from FTSE 5800. Hope all goes well - AR |
||||
| 01-02-12 | ||||
|
|
||||
|
|
||||
|
jazz club elliottwave, golden cross,weve all seen them, i do look at them its my nature and mentality -----however sometimes there is no rational logic as to whats going on, selling/buying this share could tank at any momment ,ask the boys on this site there all v sensible,enjoy ride i think it will fun for a while yet[i hope].
|
||||
| 01-02-12 |
Buy
Re: Today's news
|
2 |
||
|
|
||||
|
|
||||
|
i just took a hit in at 45p sold at 22p gave up felt at the time it was a basket case timing all wrong ,the picture is clearer theres more happening ,funding is sorted ,and new products in the making.
there momentum lets hope it keeps going £1 would be good=10p sooooo on that basis it was 60p 5 yrs ago =£6 i reckon stormdog,blackdogOne and all intresting times ahead getting complely carried away £8.50 and im retiring |
||||
|
|
||||
They have not been approved or issued by Interactive Investor Trading Limited.
Editor's Pick:
Emerging markets should perform well in 2012Editor's Pick:
View from the top: Tangiers Petroleum interviewEditor's Pick:
Glenstrata's just a silly word. Stick to big dividendsEditor's Pick:
Bulls should head for ChinaEditor's Pick:
Oil and gas investment outlook

